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Abstract: Patients with osteoporosis and joint disabilities
represent a constant growing and challenging population to be
treated in the musculoskeletal clinical ﬁeld. Especially in the
case of total hip arthroplasty, new solutions should be devel-
oped to compensate for the double negative factors, peri-im-
plant osteolysis, and osteoporotic bone loss, affecting the qual-
ity of implant outcome. The goal of this study was then to
establish a proof of concept for orthopedic implant used as
Zoledronate delivery in osteoporotic rats, and in particular, to
verify if this approach could increase the initial implant stabil-
ity. Twenty-ﬁve female 6-month-old Wistar rats were ovariec-
tomized 6 weeks before the implantation to induce osteoporo-
sis. The animals were randomly separated in ﬁve groups
representing the different Zoledronate concentrations in the
HA coating: 0, 0.2, 2.1, 8.5, and 16 g/implant. Histomorpho-
metric measures and peri-implant bone volume fraction were
assessed and mechanical stability tests were performed. Bone
volume fraction and biomechanical results clearly illustrate the
positive effect of Zoledronate coated implants in the osteopo-
rotic rats. A remarkable result was to show the existence of a
window of Zoledronate content (0.2 to 8.5 g/implant) in
which the mechanical ﬁxation of the implant increased. We
were able to establish the proof of concept for orthopedic
implants used as a drug delivery system in osteoporotic rats.
The local bisphosphonate delivery from a calcium phosphate
coating allowed increase of the mechanical ﬁxation of an or-
thopedic implant. This study shows that orthopedic implants
containing bisphosphonates could be beneﬁcial for osteopo-
rotic patients in need of a total joint replacement. © 2005 Wiley
Periodicals, Inc. J Biomed Mater Res 76A: 133–143, 2006
Key words: osteoporosis; bisphosphonates; orthopedic im-
plant; local delivery
INTRODUCTION
Total hip arthroplasty is the method most often pre-
ferred for treatment of osteoporotic patients with femo-
ral neck fractures, being implanted with, or in the press-
ﬁt technique without use of cement.1 Initially,
uncemented total hip arthroplasty was often indicated
for younger patients (60 years old) as revision of ce-
mented prosthesis is very cumbersome and potentially
damaging to the bone. However, the uncemented im-
plants are also more and more used in older patients2
due to the mean life expectancy increase. Uncemented
hip implants have also shown excellent results for difﬁ-
cult orthopedic situations such as revisions.3 This tech-
nique was motivated by the fact that poor durability of
cemented ﬁxation was observed in revision due to low
bone quality. Similarly, uncemented hip implant may
also be an attractive technique in osteoporotic situations.
Indeed, recently it has been shown that osteoporotic
bone as a factor by itself does not compromise the early
results of uncemented hip implant.4
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Long-term survival of uncemented hip components
is highly dependent on biological ﬁxation. The initial
ﬁxation of the implant is crucial for the success of the
implant.5,6 Osteoconductive coatings such as hydroxy-
apatite have been developed to increase implant ﬁxa-
tion with various amounts of success.7 Despite several
potential advantages of uncemented implants in re-
gard to cemented ones, the clinical results are still
superior for the cemented implants.8
Recently, a pharmacological approach with bisphos-
phonate has been tested in an animal study to increase
the implant outcome.9 The basic idea was to decrease
the primary failure mode, which is aseptic loosening
following peri-implant osteolysis.10 Results of two dif-
ferent clinical studies, using a treatment of 10 mg
Alendronate daily for 6 months11 or for 2 years12
showed a reduction of peri-implant bone loss in the
treated groups. In both studies, differences became
evident after 3 months. Similar results were obtained
with cyclic Ethidronate therapy.13
In parallel, it has been shown that signiﬁcant bone
loss, up to 14%, arise during the ﬁrst 3 months after
total hip arthroplasty.14 It would be important for
initial implant stability to decrease the time delay for
the bisphosphonate to reach the peri-implant bone.
Systemic delivery of bisphosphonate may then not be
an optimal delivery mode for the prevention of peri-
implant bone loss. Indeed, a local drug delivery sys-
tem would seem more appropriate. This approach
would allow to directly target the peri-implant bone,
and would then probably increase the bisphosphonate
efﬁciency. Indeed, recently a coated implant surface
with bisphosphonate stimulated new bone formation
around the implant15 and increased mechanical stabil-
ity.16 The combination of hydroxyapatite (HA) coating
and bisphosphonate would be especially interesting,
as hydroxyapatite is widely used in orthopedic im-
plants and bisphosphonates are known to be easily
combined with HA. To this end, we have extensively
characterized the combination of calcium phosphate
with Zoledronate to better understand and control the
release mode of this bisphosphonate.17,18
The goal of this study was then to establish a proof
of concept for orthopedic implants using Zoledronate
delivery in osteoporotic rats, and in particular, to ver-
ify if this approach could increase the initial implant
stability.
MATERIALS AND METHODS
Osteoporotic rats
Twenty-ﬁve female 6-month-old Wistar rats were used for
this experiment. The animals had free access to normal diet.
The rats were ovariectomized 6 weeks before the implanta-
tion to induce osteoporosis. The animals were randomly
separated into ﬁve groups representing the different Zoledr-
onate concentrations in the HA coating: 0, 0.2, 2.1, 8.5, and 16
g/implant (Table I). Three rats died of causes unrelated to
the study. Each rat received two implants containing the
same Zoledronate content, one in each femoral condyle. In
each animal, one condyle was used for bone volume fraction
measurement and histomorphometric measurements with
SEM, while the contralateral condyle was used for -CT and
biomechanical pullout tests.
Implants and Zoledronate
Titanium alloy (TA6V) cylinders (diameter 3 mm; length 5
mm) were plasma coated with hydroxyapatite (thickness: 20
m; cristallinity index 62%). Zoledronate (1-hydroxy-2-[(1H-
imidazole-1-yl)ethylidene] 1-bisphosphonic acid disodium
salt) was supplied by Novartis Pharmaceuticals AG, Basel,
Switzerland.
Zoledronate coating
Calcium phosphate ceramics have been recently devel-
oped for Zoledronate delivery, and have been extensively
described in previous work.17,18 In summary, the chemical
association of Zoledronate with the HA coating was carried
out by soaking the implants in Zoledronate solution in ul-
trapure water. No stirring of the reaction vessel was per-
formed to prevent any mechanical erosion of the HA coat-
ing. Fifty implants were immersed for 48 h in 5 mL of
aqueous Zoledronate solutions of various concentration: 0,
2.25 106, 2.25 105, 2.25 104, and 2.25 103 mol L1,
leading to modiﬁed coatings. Then, the remaining amount of
Zoledronate in the supernatant at the end of the reaction was
determined as previously described.16,18 By difference with
the initial amount of Zoledronate present in solution, the
Zoledronate-loading onto the implants was deduced,
namely 0 (corresponding to the control), 0.2, 2.1, 8.5, and 16
g of Zoledronate per implant. The presence of Zoledronate
on the modiﬁed implants was investigated in the case of the
coating loaded with 16 g/implant; for that purpose the
calcium phosphate coating was removed from the implant,
and a solid-state 31P CP-MAS NMR spectrum of the result-
ing powder clearly showed a weak signal in the expected
range for Zoledronate (10–20 ppm), along with the reso-
TABLE I
Number of Rats per Condition and Femur
(Slices) per Test
Conditions Rats
SEM
Histomorphometry
-CT and
Biomech. Tests
Control 5 5 (40) 4
0.2 g/implant 5 5 (35) 4
2.1 g/implant 5 3 (27) 3
8.5 g/implant 5 5 (42) 4
16 g/implant 5 4 (39) 4
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nance corresponding to the calcium phosphate [2.7 (strong)
and 6 (weak) ppm]. Using SEM, no alteration of the coating
due to the grafting process could be measured (Fig. 1).
In vivo implant protocol
The protocol for the animal experiment was approved
by the local Ethical Committee for Animal studies of the
National Veterinary School of Nantes. Animals were kept
at the Experimental Surgery Laboratory of the Nantes
University according to European Community guidelines
for the care and use of laboratory animals (DE86/609/
CEE). Surgical procedures were conducted under general
anesthesia using intraperitoneal injection of sodium thio-
pental associated with subcutaneous injection of mor-
phine sulfate. Bilateral implantations were performed at
the distal end of the femurs, at the epiphyso–metaphyseal
junction. After lateral arthrotomy of the knee joint, the
lateral condyle was exposed and drilled perpendicularly
to the long axis of the femur. The drilling procedure was
performed with two successive bits (2.2 and 2.8 mm in
diameter) on a low speed rotative dental handpiece and
under sterile saline irrigation. Hemostasis of the bone
cavity was controlled with sterile gauges and the coated
implant was then gently inserted into the cavity under
digital pressure. The surgeon was blinded for the Zoledr-
onate loading of the implant. Articular and cutaneous
tissues were closed in two separate layers. After surgery,
all the animals were allowed to move freely in their cages.
Animals were killed 3 weeks after implantation by intra-
cardiac injection of overdosed sodium pentobarbital, after
induction of intraperitoneal general anesthesia. Using
the -CT images, it was established that the position of
the implants in the condyle was similar for all animals
(Fig. 2).
SEM
After overdosed injection, the rats femoral ends used for
SEM were immediately dissected, ﬁxed in glutaraldehyde
solution and stored in a 4% paraformaldehyde, 0.1% glutar-
aldehyde in 0.08 M cacodylate buffer. Using a handpiece, the
condyle was sawed off 1 cm above the implant. The sample
was dehydrated in a series of alcohol solutions. The ﬁrst
impregnation step was to soak the sample in a mixture of
50% alcohol 100° and 50% methyl-methacrylate MMA
Figure 1. An implant with the HA coating (2.1 g Zoledronate per implant) was observed with a LEO 1450VP scanning
electron microscope (LEO, Cambridge, UK). (A) Shows the thickness of the coating with respect to the titanium implant, while
(B) clearly highlights the structure of the HA coating. Both SEM pictures were performed in backscattered mode.
Figure 2. To check the insertion depth of the implants, -CT measurements where performed at the end of the experiments
(3 weeks). It was established that the insertion depth was almost the same for all the implants. Exemples of the obtained
results are shown. The hollow implant is shown in white, the bone in gray (A, 0 g/implant; B, 8.5 g/implant).
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(Fluka Chemika, Sigma Aldrich Chemie Gmbh, Steinheim,
Germany) for 24 h. The second impregnation step was to
soak the sample in pure MMA for 24 h. The ﬁrst inclusion
step was to soak the dehydrated sample for 2 h under
vacuum in a solution containing 90% MMA, 10% dibu-
tylphtalate (Fluka Chemika), and 1% benzoyl peroxyde
(Fluka Chemika). The sample was then removed from the
solution and soaked in the same solution but enhanced by
a polymerization activator (N,N dimethyl-p-toluidine)
(Fluka Chemika). The polymerization took place at 20°C
and was complete after 48 h. The samples were cut in
slices 100 m thick using a Microtome saw 1600 (Leica,
Nussloch, Germany) diamond saw. The cutting plane was
perpendicular to the implant. The slices were carbon
coated, and the number of slices per animal is reported in
Table I. The samples were then observed in a JEOL JSM
6300 scanning electron microscope (JEOL, Tokyo, Japan)
using the backscattered electron detector allowing to dis-
tinguish mineralized bone from soft tissue. Each sample
was observed at two different magniﬁcations: 10 and
23. These two magniﬁcations were chosen to assess the
inﬂuence of the biocoating close to the implant and fur-
ther away. Using Quantimet (Zeiss, Jena, Germany), the
bone volume fraction and bone surface were measured as
a function of the distance from the surface of the implant
up to a distance of 200 m on the pictures taken at a
magniﬁcation of 23. By surface of the implant it is meant
the external side of the HA-coated titanium cylinder. The
bone volume fraction is deﬁned as the ratio of the white
surface of the examined area divided by the total surface
of the examined area.
Histomorphometry
A number of histomorphometric parameters have been
measured19 and the following parameters were inﬂuenced
by the biocoating: mean length of terminus-to-terminus
struts (Tm  Tm/TSL), mean length of node-to-terminus
struts (Nd  Tm/TSL), node to termini ratio (Nd  Tm), mean
length of node to node struts (Nd  Nd/TSL), number of
termini in the calciﬁed skeleton (N  Tm), total strut length
(TSL). The calculations were performed using a home-writ-
ten procedure with Quantimet (Zeiss) language and are
described by Chappard.19 The trabecular bone at depth be-
tween 1 and 4 mm was used to calculate the histomorpho-
metric parameters. The parameters were calculated as a
function of Zoledronate content.
-CT
Twenty femurs were scanned by -CT before preparing
them for the biomechanical tests. A Scanco Medical CT40
scanner (Scanco Medical, Bassersdorf, Switzerland) was
used at 70 kVp with slices every 16 m. -CT data was
Gauss ﬁltered and segmented to obtain three phases: bone,
marrow, and implant. Using the SCANCO software, the
trabecular bone volume fraction was calculated around the
implant using a concentric 500 m radius ring and centered
on the cylindrical implant. The bone volume fraction was
calculated as the ratio of the number of voxels belonging to
the trabecular bone and the total number of voxels belong-
ing to the total volume of the cylindrical ring (Fig. 3).
Biomechanical tests
After careful removal of all tendons and other soft tissues
around the emerging part of the implant, a mold was made
out of PMMA for each bone to evenly distribute the stresses
and to safely pull out the implant from the condyle (Fig. 4).
A tensile testing machine (Instron, Canton, USA) equipped
with a 1000 N gauge was used. The implants were pulled
with a steady speed of 1 mm/min. Displacement versus
Figure 3. The data obtained with the -CT shows a 3D
view of the implanted condyles. The implant is shown in
gray, the bone in yellow, and the region of interest in red.
The region of interest can be numerically extracted and bone
density can be quantiﬁed.
Figure 4. An individual mold was manufactured for each
femur to guarantee the alignment of the implant and the
pullout force. The embedded femur is placed in a steel
frame. This frame is mounted onto a tensile testing machine.
136 PETER ET AL.
force was registered and used for the determination of the
maximal pullout force.
Statistics
For the SEM, the number of slices per animal was ac-
counted for as repetition of histomorphometric parameters
and volume fraction measurement of the same animal. One-
way ANOVA and Fisher’s test were used to determine the
statistical signiﬁcance of differences in the results. A proba-
bility value of p  0.05 was considered to be statistically
signiﬁcant.
RESULTS
SEM
The SEM pictures shown in Figure 5 clearly illus-
trate the positive effect of Zoledronate-coated im-
plants on the peri-implant bone volume fraction in the
osteoporotic rats. In the case of the coating containing
no Zoledronate, the bone peri-implant volume frac-
tion is low and the bone does not grow around the
implant, whereas in the case of the implant containing
16 g of Zoledronate, the bone grows around the
implant and therefore the peri-implant bone volume
fraction is high.
The inﬂuence of the Zoledronate content on the
bone remodeling is shown in Figure 6, where the bone
volume fraction is plotted versus the distance from the
implant’s coating. In the ﬁrst 20 m, the densities
around the implant loaded with any Zoledronate con-
tent are higher than the bone volume fraction around
the implant without Zoledronate (p  0.05). With in-
creasing distance two groups of implants appear,
which are statistically different: the ﬁrst group in-
cludes the three lowest Zoledronate contents (0, 0.2,
and 2.1 g/implant), which decreases with the dis-
tance to the implant’s surface to reach a value of 0.4,
Figure 5. SEM pictures of two rat condyles at a magniﬁcation of 10 (A,B) and 23 (C,D). (A) the bone structure of a
condyle implanted with an HA-coated implant containing no Zoledronate, and (B) the bone structure of the condyle
containing an implant coated with HA grafted with 16 g of Zoledronate. The same implants and their peri-implant bone are
shown in (C) and (D) for the coatings loaded with 0 and 16 g of Zoledronate, respectively, at a magniﬁcation of 23.
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while the second group (including the two highest
Zoledronate doses) reached a bone volume fraction of
0.6 (p  0.05). Only the highest Zoledronate content
slightly increased the bone volume fraction at a dis-
tance of 1400 m when compared to all the other
cases.
Histomorphometry
The implant coated with 0.2 g/implant signiﬁ-
cantly inﬂuenced all the histomorphometric parame-
ters quantiﬁed (p  0.05) (Fig. 7). Four parameters
were increased (Tm  Tm/TSL, Nd  Tm/TSL, Nd 
Nd/TSL, N  Tm) and two were decreased (TSL, Nd 
Tm ratio). The total strut length (TSL) clearly demon-
strated a Zoledronate content effect.
-CT
The bone volume fraction around the implant con-
taining 0.2 g of Zoledronate is lower than when no
Zoledronate is present (not signiﬁcant) (Fig. 8). By
further increasing the Zoledronate content of the coat-
ing, the bone volume fraction increases to reach a
plateau with a coating containing 8.5 g/implant. Fur-
ther increase of the Zoledronate content does not in-
crease the bone volume fraction, but keeps it at the
same value as the bone around the implant containing
8.5 g of Zoledronate. The implants containing the
two highest Zoledronate contents generate bone den-
sities which are signiﬁcantly higher than the bone
densities generated around the implants containing 0
and 0.2 g of Zoledronate (p  0.05). In addition, the
coating loaded with 2.1 g of Zoledronate generates a
bone signiﬁcantly denser than the bone around the
implants containing 0.2 g (p  0.05).
Biomechanical tests
The maximal pullout force increased with increas-
ing Zoledronate content up to a dose of 8.5 g/im-
plant (Fig. 9). The maximal pullout force of the im-
plants loaded with 16 g decreased compared to the
pullout forces obtained with 2.1 and 8.5 g/implant
but still remained above the control. Statistically, the
coating loaded with 8.5 g Zoledronate leads to an
increase of the maximal pullout force compared to the
pullout force obtained with the implant not containing
any Zoledronate (p  0.05). The other cases are statis-
tically not different from each other.
Correlations between bone volume fraction and
biomechanical tests
The correlation factors R2 between the pullout
forces and the densities taken at six distances from the
implant’s surface (6, 12, 18, 48, 57, and 200 m) are
shown in Figure 10. The correlation is very good for
the distances of 6, 12, and 18 m with R2 values of
0.92, 0.92, and 0.81, respectively. With increasing dis-
tance to the implant’s surface, the correlation curve
drops rapidly to reach values close to zero for larger
distances.
DISCUSSION
Patients with osteoporosis and joints disabilities
represent a constant growing and challenging popu-
lation to be treated in the musculoskeletal clinical
ﬁeld. Especially in the case of total hip arthroplasty,
new solutions should be developed to compensate for
the double negative factors, peri-implant osteolysis,
and osteoporotic bone loss, affecting implants out-
come. Studies over the past 2 decades have strongly
implicated osteoclasts as the major cause of the bone
lysis leading to implant failure.20 It has been proposed
to use bisphosphonate treatment to decrease peri-im-
plant bone lysis.9 This approach is then especially
adapted for the situation involving osteoporotic pa-
tients. However, recent clinical studies have shown
that systemic bisphosphonate treatment following the
prosthesis implantation reduced peri-implant bone
loss only after 3 months,11,12 while signiﬁcant bone
loss arises during this initial period of 3 months.14
Local bisphosphonate delivery may then represent an
interesting approach to bring the drug immediately
Figure 6. Bone volume fraction as function of the distance
from implant surface at different Zoledronate contents.
Close to the implant, all the implants containing Zoledronate
lead to a high bone volume fraction. With increasing dis-
tance, the bone volume fraction decreases around the coat-
ings containing the two lowest Zoledronate contents, while
the bone volume fraction increases around the implants
containing the two highest drug contents (mean  SEM).
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into the peri-implant bone. In this study, we evaluated
the possibility of using the orthopedic implants as a
bisphosphonate carrier in an osteoporotic rat model.
We noted a clear positive effect on bone density and
stability for the implant coated with Zoledronate. The
peri-implant bone volume fraction was higher and the
implant stability was increased in the treated groups.
Indeed, the biomechanical pull out tests showed that
the implant stability was even better than in the situ-
ation with implants inserted in nonosteoporotic
rat.16,21
These encouraging results have to be considered
with several remarks. The study was designed to de-
termine the Zoledronate-HA coating leading to an
optimal peri-implant bone volume fraction distribu-
tion, optimal from the point of view of implant ﬁxa-
tion. In this context, the most remarkable result was to
show the existence of only one Zoledronate content
Figure 7. Histomorphometric parameters as function of the Zoledronate content (mean  SEM). (A) Mean length of
terminus-to-terminus struts (Tm  Tm/TSL); (B) mean length of node-to-terminus struts (Nd  Tm/TSL); (C) mean length of
node to node struts (Nd  Nd/TSL); (D) total strut length (TSL); (E) node to termini ratio (Nd  Tm ratio); (F) number of termini
in the calciﬁed skeleton (N  Tm).
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(8.5 g/implant) for which the mechanical ﬁxation of
the implant is increased. Translation of this Zoledr-
onate content efﬁcacy for clinical applications may be
a nontrivial task. The in vivo model was different from
the clinical situation where implants are mechanically
loaded and induce micromotions at the bone–implant
interface. In a recent theoretical study, we have shown
that bisphosphonates may inﬂuence the bone respon-
siveness to mechanical stimulus.22 Indeed, the prob-
lem in peri-implant osteolysis is more with the ab-
sence of mechanical stimuli with the so-called stress-
shielding phenomena,23 and in this situation it has
been shown that Zoledronic acid administration led to
signiﬁcantly greater bone area, mineral content,
strength, and trabeculae number with reduced stress-
shielding osteopenia in a model of distraction osteo-
genesis.24 In a numerical study taking into account the
mechanical situation, we demonstrated that the partial
bisphosphonate coating of a hip implant may increase
its stability.25 An in vivo model with hip implant
would be helpful to conﬁrm the positive results of
local Zoledronate delivery in peri-implant bone qual-
ity.
The presented in vivo study was carried out for 3
weeks. Bisphosphonate, by affecting bone remodeling,
could also block the bone repair process. The drug at
too high concentrations could then have detrimental
effects on the ﬁxation of the implant over longer pe-
riods of time. Indeed, conﬂicting studies have re-
ported that the use of bisphosphonate can interact
with the repair of cracks and fractures, while other
studies were unable to demonstrate this phenome-
non.26,27 A very encouraging result was obtained in a
10-year follow up study of 10 mg of Alendronate daily
treatment, which was associated with sustained ther-
apeutic effects on bone volume fraction and remodel-
ing, with no indication that the antifracture efﬁcacy of
the drug was diminished.28 In addition, it has been
shown that amino-bisphosphonates (like Zoledronate)
do not impair with the fractures and cracks repair
process due to the lower dosing.29 Long-term studies
with implants used as drug delivery systems will be
the next step in this development and should also
show an increase in implant stability.
We checked that Zoledronate saturation in the im-
plant coating was not achieved.17 Basically, we have
demonstrated that there are two modes of association
between calcium phosphates (including HA) and
Zoledronate.18 The ﬁrst mode is chemisorption (via
PO3-PO4 exchange), and when saturation is achieved,
Figure 8. The bone volume fraction measured with -CT in
a 500-m radius around the implant is shown as function of
the Zoledronate content of the coating. The bone volume
fraction increases with increasing Zoledronate content and
reaches a plateau for the two highest Zoledronate contents
(mean  SEM).
Figure 9. Pullout force as function of Zoledronate content
of the coating. At low Zoledronate contents, the pullout
force increases with increasing Zoledronate content of the
coating. The pullout force reaches a maximum with a
Zoledronate content of 8.5 g/implant. By further increas-
ing the Zoledronate content of the coating, the pullout force
decreases (mean  SEM).
Figure 10. Correlation factor between the bone volume
fraction taken at distance d from the implant’s surface and
pullout force for osteoporotic rats.
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the formation of a crystalline compound, probably a
calcium salt of zoledronic acid, occurs at the surface of
the material. This crystalline compound can easily be
detected by NMR and SEM. As uncemented orthope-
dic implants are usually coated with HA, the combi-
nation of HA and Zoledronate is then an easy trans-
formation of currently adopted standard in the
orthopedic ﬁeld.
The measurements with the -CT were performed
to quantify the bone volume fraction around the
implants before subjecting them to the pullout tests.
Moreover, the contact surface between the bone and
the implant should have been measured to verify if
the presence of Zoledronate had an inﬂuence on the
failure stress. Due to the interaction between the
metallic implant and the X-rays used in the -CT,
the resolution close to the implant was low, which
prevented the calculations of peri-implant bone con-
tact surface with sufﬁcient precision. However, the
bone volume fraction measurements along the long
axis conﬁrm the Zoledronate dose effect on the bone
volume fraction.
In most in vivo studies, the effect of bisphosphonates
on the histomorphometry of bone was an increase in
trabecular number and thickness and a decrease of tra-
becular separation.24,30,31 In our study, none of those
parameters seem to be altered by the presence of Zoledr-
onate. These differencesmay be due to the fact that in the
other studies, the bisphosphonate passed through the
gastrointestinal apparatus and the blood stream before
reaching the bone, while in our case, the bisphosphonate
was directly put into contact with the bone through the
means of the HA coating. The delivery type would prob-
ably inﬂuence the bioavailability and the distribution of
bisphosphonate in the bone, and thus the peri-implant
bone volume fraction and morphology.
To control the bone remodeling around implant,
pharmacological treatment of peri-implant osteoly-
sis has been proposed with TNF antagonist systemic
treatment but without clear positive effects ob-
served.32 An indirect way of evaluating the effect of
Alendronate treatment on orthopedic implants out-
come has been performed in the canine model using
an implantable bone growth chamber.33 Alendro-
nate did not affect bone integration. The back-
ground of this study was related to the fact that
patients at high risk for osteoporosis are currently
treated with bisphosphonate, as it has been shown
that osteoporosis does not protect against the devel-
opment of coxarthrosis.34 Beside Alendronate, dif-
ferent bisphosphonates have been tested for de-
creasing peri-implant osteolysis. Iwase et al.35 used
a novel bisphosphonate (TRK-530) with inhibitor
effects on osteoclast formation and TNF expression.
They showed a decreased osteolysis in the rat oste-
olysis model with continuous infusion of particles.
The bisphosphonate was injected with the particles
making the model not clinically relevant. Despite
systemic bisphosphonates, treatment seems to suc-
cessfully increase bone mineral density and to pre-
vent bone fracture in general, a careful analysis of
the existing literature highlights that differences be-
tween skeletal sites are present. A phase III Alen-
dronate clinical trial showed that daily treatment of
Alendronate in 994 women for 3 years had a more
potent effect on bone mineral density in the spine
than in the proximal femur.36 The actual systemic
bisphosphonates delivery seems then to be inefﬁ-
cient to target proximal femoral bone. This might
explain the apparent inefﬁciency of systemic bisph-
sophonate treatment to reduce the peri-implant os-
teolysis during the ﬁrst 3 months following the be-
ginning of the treatment.11,12 Another major
disadvantage of the clinically utilized bisphospho-
nates is their poor oral absorption from the gastro-
intestinal tract, typically less than 1% is absorbed.37
All these drawbacks (low bisphosphonates uptake
especially at the proximal femur site, no optimal
administration route, low patient compliance) with
the use of the bisphosphonates advocate for further
developments in the administration route. As for
other pharmacological treatments, the drug delivery
system may present an important beneﬁcial poten-
tial.
Several studies have been recently performed to
combine implant and bisphosphonate. Tengvall38
showed an increase by 28% of the pullout force of
steel screws inserted in rat femurs by using a ﬁbrin-
ogen/pamidronate/ibandronate coating. In a study
performed with nonosteoporotic rats,16 the implants
containing 2.1 g of Zoledronate induced an in-
crease in pullout force up to 42% compared to im-
plants without Zoledronate. The combination of HA
and Zoledronate is probably more favorable than
ﬁbrinogen and bisphosphonate in the point of view
of orthopedic implant ﬁxation. Using a coating of
Pamidronate, implants inserted in immature rats
stimulated new bone formation around the implant,
suggesting a supportive osteointegration effect for
bisphosphonate.15 No information on implant sta-
bility and quantity of bisphosphonate coated was
given.
In the present study, the amount of Zoledronate
coated on the implant was precisely determined, al-
lowing evaluation of its dose effect on the peri-implant
bone. The coating containing 8.5 g of Zoledronate
per implant induced the highest implant mechanical
stability, a key property for the long-term implant
survival. The correlation between bone volume frac-
tion and mechanical stability showed that the ﬁrst 20
m are of uttermost importance for the mechanical
ﬁxation of an implant. Therefore, the approach of in-
creasing the peri-implant volume fraction by a local
drug delivery becomes even more justiﬁed.
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CONCLUSION
In conclusion, this study was able to establish the
proof of concept for orthopedic implants used as a
drug delivery system in osteoporotic rats. The local
bisphosphonate delivery from a calcium phosphate
coating allowed to increase the mechanical ﬁxation of
an orthopedic implant. Moreover, we showed that the
increase in peri-implant bone volume fraction is de-
pendent on the Zoledronate content of the coating.
The mechanical stability of an implant is correlated to
the bone volume fraction in the 20 m of bone around
the implant advocating for a local delivery of the
bisphosphonate. Orthopedic implant as bisphospho-
nate delivery may then represent an interesting ap-
proach for osteoporotic patients in need of a total joint
replacement.
We thank Novartis Pharma Research (Basel) for a gener-
ous gift of Zoledronate and J.R. Green (Novartis Pharma
Research) for fruitful discussion. We thank Paul Pilet for
technical assistance.
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